HRP20192341T1 - 3.alfa.-etinil, 3.beta.-hidroksi-5.alfa.-pregnan-20-oksim za upotrebu u liječenju poremećaja cns - Google Patents
3.alfa.-etinil, 3.beta.-hidroksi-5.alfa.-pregnan-20-oksim za upotrebu u liječenju poremećaja cns Download PDFInfo
- Publication number
- HRP20192341T1 HRP20192341T1 HRP20192341TT HRP20192341T HRP20192341T1 HR P20192341 T1 HRP20192341 T1 HR P20192341T1 HR P20192341T T HRP20192341T T HR P20192341TT HR P20192341 T HRP20192341 T HR P20192341T HR P20192341 T1 HRP20192341 T1 HR P20192341T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- alpha
- diluent
- steroid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 8
- 239000003085 diluting agent Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 208000015114 central nervous system disease Diseases 0.000 claims 6
- 150000003431 steroids Chemical class 0.000 claims 6
- 230000027758 ovulation cycle Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 206010016256 fatigue Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000013066 combination product Substances 0.000 claims 2
- 229940127555 combination product Drugs 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- RSRDWHPVTMQUGZ-QYYVTAPASA-N 1-[(5r,8r,9s,10s,13s,14s,17s)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 RSRDWHPVTMQUGZ-QYYVTAPASA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000012639 Balance disease Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010027940 Mood altered Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010021654 increased appetite Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000007510 mood change Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940127234 oral contraceptive Drugs 0.000 claims 1
- 239000003539 oral contraceptive agent Substances 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. 3α-etinil, 3β-hidroksi, 5α-pregnan-20-oksim ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutska formulacija koja obuhvaća spojeve kao što je definirano u patentnom zahtjevu 1, u mješavini s farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem.
3. Spoj kako je definiran u patentnom zahtjevu 1, za upotrebu u terapiji.
4. Spoj kako je definiran u patentnom zahtjevu 1, za upotrebu u postupku liječenja:
(a) poremećaja CNS povezanog sa steroidom;
(b) stanja ili simptoma uzrokovanih razvijanjem tolerancije nakon izlaganja 3-alfa-hidroksi-5-alfa/beta-steroidima;
(c) stanja koje je pod utjecajem odvikavanja/apstinencije izlaganja 3-alfa-hidroksi-5-alfa/beta-steroidima;
(d) jedne ili više nuspojave anti-inflamatornog steroida;
(e) jedne ili više nuspojave postmenopauzalne terapije; i/ili
(f) jedne ili više nuspojave oralnog kontraceptiva.
5. Spoj za upotrebu prema patentnom zahtjevu 4, gdje poremećaj CNS povezan sa steroidom je izabran iz grupe koju čine epilepsija, epilepsija ovisna o menstrualnom ciklusu, depresija, depresija povezana sa stresom, migrena, umor i posebno umor koji je povezan sa stresom, predmenstrualni sindrom, predmenstrualni disforični poremećaj, promjene raspoloženja povezane sa menstrualnim ciklusom, minimalno kognitivno oštećenje, kognitivno oštećenje, promjene u memoriji povezane s menstrualnim ciklusom, promjene u memoriji povezane sa stresom, poteškoće u učenju povezane sa stresom, hepatička encefalopatija, Downov sindrom, Alzheimerova bolest, poteškoće u koncentraciji povezane s menstrualnim ciklusom, poremećaji spavanja povezani s menstrualnim ciklusom i umorom, povećan apetit, prejedanje i pretilost, relaps zloupotrebe alkohola i opojnih sredstava, poremećaji ravnoteže, ’moment’ poremećaji i poteškoće u koordinaciji.
6. Spoj za upotrebu prema patentnom zahtjevu 5, gdje poremećaj je hepatička encefalopatija.
7. Spoj za upotrebu prema patentnom zahtjevu 6, gdje hepatička encefalopatija je Tip A hepatičke encefalopatije, Tip B hepatičke encefalopatije, Tip C hepatičke encefalopatije, minimalna hepatička encefalopatija, ili otvorena hepatička encefalopatija.
8. Spoj za upotrebu kao što je navedeno u patentnom zahtjevu 5, gdje je poremećaj Downov sindrom ili Alzheimerova bolest.
9. Kombinirani proizvod koji obuhvaća:
(A) spoj kao što je definirano u patentnom zahtjevu 1; i
(B) bar jedno drugo terapeutsko sredstvo koje je korisno u liječenju poremećaja CNS povezanog sa steroidom,
pri čemu svaka od komponenti (A) i (B) je formulirana u mješavini s farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem.
10. Kombinirani proizvod kao što je navedeno u patentnom zahtjevu 9 koji obuhvaća farmaceutsku formulaciju uključujući spoj kao što je definirano u patentnom zahtjevu 1, bar jedno drugo farmaceutsko sredstvo koje je korisno u liječenju poremećaja CNS povezanog sa steroidom, i farmaceutski prihvatljivo pomoćno sredstvo, razrjeđivač ili nosač.
11. Kombinirani proizvod kao što je definirano u patentnom zahtjevu 9, koji obuhvaća komplet dijelova koji sadrže komponente:
(a) farmaceutska formulacija koja obuhvaća spoj formule I kao što je definirano u patentnom zahtjevu 1, u mješavini s farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem; i
(b) farmaceutska formulacija koja obuhvaća bar jedno drugo terapeutsko sredstvo koje je korisno u liječenju poremećaja CNS povezanog sa steroidom u mješavini s farmaceutski prihvatljivim pomoćnim sredstvom, nosačem ili razrjeđivačem,
gdje komponente (a) i (b) su svaka dana u obliku koji je pogodan za davanje zajedno sa drugim.
12. Postupak za dobivanje spoja formule I kao što je definirano u patentnom zahtjevu 1, gdje proces obuhvaća reakciju 3α-etinil, 3β-hidroksi, 5α-pregnan-20-ona sa hidroksilaminom.
13. Postupak za dobivanje farmaceutske formulacije kao što je definirano u patentnom zahtjevu 2, gdje postupak obuhvaća dovođenje u vezu spoja kao što je definirano u patentnom zahtjevu 1 s farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem.
14. Postupak za dobivanje kombiniranog proizvoda kako je definirano u bilo kojem od patentnih zahtjeva 9 do 11, gdje postupak obuhvaća dovođenje u vezu spoja kao što je definirano u patentnom zahtjevu 1 s drugim terapeutskim sredstvom koje je korisno u liječenju poremećaja CNS povezanog sa steroidom, i bar jednim farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1500018 | 2015-01-12 | ||
PCT/GB2016/050059 WO2016113549A1 (en) | 2015-01-12 | 2016-01-11 | 3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of cns disorders |
EP16704468.4A EP3245217B1 (en) | 2015-01-12 | 2016-01-11 | 3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20192341T1 true HRP20192341T1 (hr) | 2020-04-03 |
Family
ID=55358006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20192341TT HRP20192341T1 (hr) | 2015-01-12 | 2019-12-30 | 3.alfa.-etinil, 3.beta.-hidroksi-5.alfa.-pregnan-20-oksim za upotrebu u liječenju poremećaja cns |
Country Status (26)
Country | Link |
---|---|
US (1) | US10351589B2 (hr) |
EP (1) | EP3245217B1 (hr) |
JP (1) | JP6712599B2 (hr) |
KR (1) | KR102534043B1 (hr) |
CN (1) | CN107207560B (hr) |
AR (1) | AR103384A1 (hr) |
AU (1) | AU2016207865B2 (hr) |
BR (1) | BR112017014733B1 (hr) |
CA (1) | CA2971302C (hr) |
CY (1) | CY1122588T1 (hr) |
DK (1) | DK3245217T3 (hr) |
ES (1) | ES2764454T3 (hr) |
HK (1) | HK1244288A1 (hr) |
HR (1) | HRP20192341T1 (hr) |
HU (1) | HUE046759T2 (hr) |
IL (1) | IL253037B (hr) |
MX (1) | MX2017008953A (hr) |
NZ (1) | NZ733245A (hr) |
PL (1) | PL3245217T3 (hr) |
PT (1) | PT3245217T (hr) |
RS (1) | RS59736B1 (hr) |
RU (1) | RU2712786C2 (hr) |
SI (1) | SI3245217T1 (hr) |
TW (1) | TWI748936B (hr) |
WO (1) | WO2016113549A1 (hr) |
ZA (1) | ZA201704287B (hr) |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2713061A (en) | 1951-04-06 | 1955-07-12 | Schering Ag | 3-methyl androstanes |
FR1463755A (fr) | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
US3173932A (en) | 1962-11-02 | 1965-03-16 | American Cyanamid Co | 15-substituted estra-1, 3, 5(10)-trienes |
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
FR2685332A1 (fr) | 1991-12-20 | 1993-06-25 | Roussel Uclaf | Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments. |
AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
ES2235187T3 (es) | 1995-06-06 | 2005-07-01 | Euro-Celtique S.A. | Esteroides neuroactivos de las series del androstano y el pregnano. |
CN1270718C (zh) | 1998-03-11 | 2006-08-23 | 托布乔恩·贝克斯托罗姆 | 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 |
US6593321B2 (en) | 2001-06-11 | 2003-07-15 | Southwest Foundation For Biomedical Research | 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
US7781421B2 (en) | 2003-05-29 | 2010-08-24 | Washington University | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods |
EP2319581B1 (en) | 2004-11-26 | 2015-02-25 | UCL Business PLC | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
WO2007103162A2 (en) | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
PL2097437T3 (pl) * | 2006-11-21 | 2015-12-31 | Umecrine Cognition Ab | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń OUN |
GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
WO2010040020A1 (en) | 2008-10-02 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
ES2728948T3 (es) | 2009-06-08 | 2019-10-29 | Ucl Business Plc | Tratamiento de la inflamación cerebral usando Fenilacetato de L-Ornitina |
WO2015048818A1 (en) | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Diagnosing, grading, monitoring, and treating hepatic encephalopathy |
JP6543633B2 (ja) | 2014-01-29 | 2019-07-10 | ウメクライン コグニション アーベー | 肝性脳症の治療において使用するためのステロイド化合物 |
-
2016
- 2016-01-08 TW TW105100507A patent/TWI748936B/zh active
- 2016-01-08 AR ARP160100046A patent/AR103384A1/es unknown
- 2016-01-11 BR BR112017014733-5A patent/BR112017014733B1/pt active IP Right Grant
- 2016-01-11 CA CA2971302A patent/CA2971302C/en active Active
- 2016-01-11 ES ES16704468T patent/ES2764454T3/es active Active
- 2016-01-11 RU RU2017126160A patent/RU2712786C2/ru active
- 2016-01-11 RS RS20191649A patent/RS59736B1/sr unknown
- 2016-01-11 DK DK16704468T patent/DK3245217T3/da active
- 2016-01-11 EP EP16704468.4A patent/EP3245217B1/en active Active
- 2016-01-11 PL PL16704468T patent/PL3245217T3/pl unknown
- 2016-01-11 WO PCT/GB2016/050059 patent/WO2016113549A1/en active Application Filing
- 2016-01-11 MX MX2017008953A patent/MX2017008953A/es unknown
- 2016-01-11 HU HUE16704468A patent/HUE046759T2/hu unknown
- 2016-01-11 KR KR1020177018665A patent/KR102534043B1/ko active IP Right Grant
- 2016-01-11 CN CN201680005413.6A patent/CN107207560B/zh active Active
- 2016-01-11 NZ NZ733245A patent/NZ733245A/en unknown
- 2016-01-11 SI SI201630557T patent/SI3245217T1/sl unknown
- 2016-01-11 PT PT167044684T patent/PT3245217T/pt unknown
- 2016-01-11 AU AU2016207865A patent/AU2016207865B2/en active Active
- 2016-01-11 JP JP2017536577A patent/JP6712599B2/ja active Active
- 2016-01-11 US US15/542,800 patent/US10351589B2/en active Active
-
2017
- 2017-06-20 IL IL253037A patent/IL253037B/en active IP Right Grant
- 2017-06-23 ZA ZA2017/04287A patent/ZA201704287B/en unknown
-
2018
- 2018-03-20 HK HK18103827.3A patent/HK1244288A1/zh unknown
-
2019
- 2019-12-20 CY CY20191101342T patent/CY1122588T1/el unknown
- 2019-12-30 HR HRP20192341TT patent/HRP20192341T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7305205B2 (ja) | N4-ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 | |
JP6381751B2 (ja) | パーキンソン病の治療のための新規治療方法 | |
US20180318301A1 (en) | Formulations of azaindole compounds | |
JP2015038149A5 (hr) | ||
US20160251353A1 (en) | Inhibitors of influenza viruses replication | |
JP2023512666A (ja) | N4-ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
MY159816A (en) | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them | |
CA2994162A1 (en) | Glutamine antagonists for the treatment of cognitive deficits | |
Yang et al. | Lianhua‐Qingwen Displays Antiviral and Anti‐Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model | |
JP2024069257A (ja) | L-4-クロロキヌレニンの剤形及び治療的使用 | |
Du et al. | Antiviral effects and mechanisms of Yinhuapinggan granule against H1N1 influenza virus infection in RAW264. 7 cells | |
HRP20192341T1 (hr) | 3.alfa.-etinil, 3.beta.-hidroksi-5.alfa.-pregnan-20-oksim za upotrebu u liječenju poremećaja cns | |
BRPI0605893A (pt) | composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina | |
RU2010107177A (ru) | Новые комбинации нерамексана для лечения нейродегенеративных расстройств | |
TW201008902A (en) | Aliskiren monofumarate and processes for preparation thereof | |
HRP20230735T1 (hr) | Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta | |
CN106860464A (zh) | 用于联合抗病毒治疗的药物组合物及应用 | |
JP2627914B2 (ja) | プロスタグランジン類の選択的作用増強剤 | |
US2994703A (en) | Succinimide compounds | |
WO2022024649A1 (ja) | 感冒剤及び抗ウイルス剤 | |
JP2014507475A5 (hr) | ||
Yamauchi et al. | Molecular Mechanism of Learning and Memory Based on the Research for Ca^ 2^+/Calmodulin-dependent Protein Kinase II | |
ITMI20011642A1 (it) | Uso del cimetropio bromuro per la preparazione di farmaci ad attivita' antiallergica | |
Kumari et al. | Histopathological changes induced by desvenlafaxine in cerebellum of Swiss albino mice |